Intra-Cellular Therapies (ITCI) News Today → Why Is Gold On a MASSIVE rally? (From Huge Alerts) (Ad) Free ITCI Stock Alerts $65.00 -1.53 (-2.30%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:38 PM | marketbeat.comNicholas Investment Partners LP Trims Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Nicholas Investment Partners LP reduced its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 85.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,244 shares of the biophaMay 13, 2024 | americanbankingnews.comCantor Fitzgerald Brokers Increase Earnings Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)May 12, 2024 | marketbeat.comSwiss National Bank Sells 19,400 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Swiss National Bank trimmed its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 170,400 shares of the biopharmaceutical cMay 11, 2024 | americanbankingnews.comLeerink Partnrs Brokers Boost Earnings Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)May 10, 2024 | markets.businessinsider.comMaintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study OutlookMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Boosted by Leerink PartnrsIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q2 2024 EPS estimates for shares of Intra-Cellular Therapies in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now exMay 10, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. Forecasted to Post FY2025 Earnings of $1.50 Per Share (NASDAQ:ITCI)May 9, 2024 | marketbeat.comAnalysts Issue Forecasts for Intra-Cellular Therapies, Inc.'s FY2025 Earnings (NASDAQ:ITCI)Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for Intra-Cellular Therapies in a research note issued on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceuticaMay 9, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Releases Earnings Results, Beats Expectations By $0.15 EPSIntra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The company had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. During the same period in the previous year, the firm earned ($0.46) EPS. Intra-Cellular Therapies's revenue was up 52.0% on a year-over-year basis.May 8, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Given Buy Rating at Needham & Company LLCMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...May 7, 2024 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations with Caplyta Sales SurgeMay 7, 2024 | msn.comITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comIntra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA SalesMay 7, 2024 | marketbeat.comIntra-Cellular Therapies' (ITCI) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Intra-Cellular Therapies in a research note on Tuesday.May 7, 2024 | msn.comIntra-Cellular Therapies beats Q1 estimatesMay 7, 2024 | globenewswire.comIntra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 6, 2024 | marketbeat.comLisanti Capital Growth LLC Invests $3.79 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Lisanti Capital Growth LLC purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 52,885 shares of the biopharmaceutical company'sMay 2, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by California Public Employees Retirement SystemCalifornia Public Employees Retirement System lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,376 sharesMay 1, 2024 | marketbeat.comIntra-Cellular Therapies (ITCI) to Release Quarterly Earnings on TuesdayIntra-Cellular Therapies (NASDAQ:ITCI) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports.April 30, 2024 | globenewswire.comIntra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and WebcastApril 29, 2024 | marketbeat.comPFG Investments LLC Purchases 11,000 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)PFG Investments LLC raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 392.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,800 shares of the biopharmaceuticalApril 26, 2024 | marketbeat.comEquities Analysts Set Expectations for Intra-Cellular Therapies, Inc.'s FY2024 Earnings (NASDAQ:ITCI)Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Intra-Cellular Therapies in a research note issued on Wednesday, April 24th. Cantor Fitzgerald analyst C. Duncan now forecasts that theApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)April 24, 2024 | finance.yahoo.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 24, 2024 | globenewswire.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesApril 24, 2024 | marketbeat.comIntra-Cellular Therapies' (ITCI) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $120.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday.April 24, 2024 | investorplace.com3 Biotech Stocks With Skyrocketing Potential: April 2024April 23, 2024 | marketbeat.comCanaccord Genuity Group Boosts Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $107.00Canaccord Genuity Group boosted their price target on Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a "buy" rating in a research report on Tuesday.April 22, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $90.00Needham & Company LLC boosted their price objective on shares of Intra-Cellular Therapies from $82.00 to $90.00 and gave the company a "buy" rating in a research report on Monday.April 22, 2024 | msn.comIpsen, Skyhawk enter RNA targeting research collab in rare neurological diseasesApril 21, 2024 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Increased by Knights of Columbus Asset Advisors LLCKnights of Columbus Asset Advisors LLC boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 100.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,499 shares of the biopApril 20, 2024 | money.usnews.comIntra-Cellular Therapies IncApril 17, 2024 | globenewswire.comIntra-Cellular Therapies Prices Public Offering of Common StockApril 17, 2024 | marketbeat.comThe Goldman Sachs Group Boosts Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $77.00The Goldman Sachs Group boosted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a "neutral" rating in a report on Wednesday.April 17, 2024 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Stock Price Down 2.7%Intra-Cellular Therapies (NASDAQ:ITCI) Trading Down 2.7%April 17, 2024 | marketbeat.comQuantum Private Wealth LLC Grows Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Quantum Private Wealth LLC raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 64.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,705 shares of the biopharmaceuticApril 17, 2024 | investors.comBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy PointApril 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?April 17, 2024 | investing.comBofA ups Intra-Cellular Therapies shares target, buoyed by positive Caplyta trial resultsApril 16, 2024 | markets.businessinsider.comIntra-Cellular Therapies: Hold Rating with Increased Price Target Amid Caplyta’s Clinical SuccessApril 16, 2024 | marketbeat.comHealthInvest Partners AB Invests $877,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)HealthInvest Partners AB acquired a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 12,245 shares of the biopharmaceuticaApril 16, 2024 | globenewswire.comIntra-Cellular Therapies Announces Proposed Public Offering of Common StockApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)April 16, 2024 | msn.comIntra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment StudyApril 16, 2024 | finance.yahoo.comIntra-Cellular Launches 26% To Record High, Breaking Out After Depression Drug Scores BigApril 16, 2024 | seekingalpha.comIntra-Cellular: More Upside Possible Even After Positive MDD Treatment Data Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Is Gold On a MASSIVE rally? (Ad)Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock. This Little known Company is a uniquely structured for profit ITCI Media Mentions By Week ITCI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼1.150.53▲Average Medical News Sentiment ITCI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼105▲ITCI Articles Average Week Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: JAZZ News ASND News BPMC News CERE News CYTK News VKTX News LEGN News IONS News OGN News ELAN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITCI) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchShocking $16T Elon Musk Crypto LeakCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
